JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on TVRD stock, giving a Buy rating on May 21.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Debanjana Chatterjee’s rating is based on several compelling factors surrounding Tvardi Therapeutics. The company has successfully completed enrollment for its Phase 2 REVERT trial, which is investigating the efficacy of its STAT3 inhibitor, TTI-101, for treating idiopathic pulmonary fibrosis (IPF). This milestone is significant as it demonstrates the company’s commitment to advancing its clinical pipeline.
Additionally, interim analysis from the trial has shown a favorable trend in improving forced vital capacity (FVC) without any safety concerns at the administered doses. This progress strengthens the expectation of a positive outcome in the fourth quarter of 2025, which could serve as a pivotal moment for the stock. These developments collectively contribute to the Buy rating, reflecting confidence in Tvardi’s potential for future growth.
In another report released on May 21, Oppenheimer also initiated coverage with a Buy rating on the stock with a $65.00 price target.